Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 38
Filter
1.
J Law Med ; 13(4): 479-95, 2006 May.
Article in English | MEDLINE | ID: mdl-16756217

ABSTRACT

In the face of a potential bird flu pandemic, Australian Federal Health Minister, Tony Abbott, has recently dismissed expert advice that the government should begin, or even publicly consider, authorising generic manufacturers to produce antivirals, such as Tamiflu and Relenza, under patent via non-voluntary licensing methods. This is despite the fact that the demand for antivirals in Australia, and throughout the world, cannot be met by manufacturers under the control of limited patent owners alone. This article proposes that Australian patent law, which allows for non-voluntary licensing when it comes to important public health issues that affect Australian citizens, is relevant in meeting the demand for increased antiviral treatments during a possible bird flu pandemic, domestically and abroad. It argues that the Australian Government must go beyond what is currently being done and investigate and pursue such options.


Subject(s)
Antiviral Agents/supply & distribution , Drugs, Generic/supply & distribution , Influenza, Human/drug therapy , Legislation, Drug , Patents as Topic/legislation & jurisprudence , Public Health/legislation & jurisprudence , Acetamides/supply & distribution , Animals , Australia , Birds , Guanidines/supply & distribution , Health Services Needs and Demand , Humans , Influenza A Virus, H5N1 Subtype/drug effects , Influenza in Birds , Oseltamivir , Pyrans/supply & distribution , Sialic Acids/supply & distribution , Zanamivir
4.
BMJ ; 332(7547): 975-6, 2006 Apr 22.
Article in English | MEDLINE | ID: mdl-16627527
10.
Infect Control Hosp Epidemiol ; 26(11): 852-4, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16320980

ABSTRACT

The outbreak of H5N1 avian influenza in Asia has reignited concerns about an influenza pandemic. It is clear that influenza vaccine will be in short supply (or nonexistent) early in an influenza pandemic. Without vaccine, the role of antiviral agents, especially oseltamivir, in treatment and prophylaxis is of paramount importance. Unfortunately, the government cannot possibly stockpile enough oseltamivir to provide long-term prophylaxis or treatment for every healthcare worker in the United States. We think that hospitals should consider stockpiling oseltamivir, and we provide a strategy for doing so at a reasonable cost.


Subject(s)
Acetamides/supply & distribution , Antiviral Agents/supply & distribution , Disaster Planning , Disease Outbreaks/prevention & control , Hospitals/supply & distribution , Influenza, Human/prevention & control , Acetamides/therapeutic use , Antiviral Agents/therapeutic use , Disease Outbreaks/economics , Humans , Influenza A Virus, H5N1 Subtype , Influenza, Human/drug therapy , Influenza, Human/economics , Influenza, Human/epidemiology , Oseltamivir
SELECTION OF CITATIONS
SEARCH DETAIL
...